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ABSTRACT
Introduction: The co-infection Trypanosoma cruzi/HIV has been described as a clinical event 
of great relevance. The objective of this study was to describe clinical and epidemiological 
aspects published in literature. Methods: It is a systematic review of a descriptive nature 
from the databases Medline, Lilacs, SciELO, Scopus, from 1980 to 2010. Results: There 
were 83 articles (2.8 articles/year) with a total of 291 cases. The co-infection was described 
in 1980 and this situation has become the defining AIDS clinical event in Brazil. This is the 
country with the highest number of publication (51.8%) followed by Argentina (27.7%). 
The majority of cases are amongst adult men (65.3%) native or from endemic regions with 
serological diagnosis in the chronic stage (97.9%) and indeterminate form (50.8%). Both 
diseases follow the normal course, but in 41% the reactivation of the Chagas disease occurs. 
The most severe form is the meningoencephalitis, with 100% of mortality without specific 
and early treatment of the T. cruzi. The medication of choice was the benznidazole on doses 
and duration normally used for the acute phase. The high parasitemia detected by direct or 
indirect quantitative methods indicated reactivation and its elevation is the most important 
predictive factor. The lower survival rate was related to the reactivation of the Chagas disease 
and the natural complications of both diseases. The role of the antiretroviral treatment on the 
co-infection cannot yet be defined by the knowledge currently existent. Conclusions: Despite 
the relevance of this clinical event there are still gaps to be filled.
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RESUMO
Introdução: A coinfecção Trypanosoma cruzi/HIV vem sendo sistematicamente descrita como 
um evento clínico de grande relevância. O objetivo deste estudo foi descrever aspectos clínicos 
e epidemiológicos publicados na literatura científica. Métodos: Trata-se de revisão sistemática, 
de natureza descritiva, a partir da busca nas bases Medline, Lilacs, SciELO, Scopus, de 1980 
a 2010. Resultados: Identificou-se 83 artigos (2,8 artigos/ano), com um total de 291 casos 
registrados. A coinfecção foi descrita em 1980 e, no Brasil, tornou-se evento clínico definidor 
de AIDS. Este é o país com maior número de publicações (51,8%), seguido pela Argentina 
(27,7%). A maioria dos casos é de homens adultos (65,3%), naturais ou procedentes de regiões 
endêmicas, com diagnóstico sorológico, na fase crônica (97,9%) e na forma indeterminada 
(50,8%). As duas doenças evoluem naturalmente, mas em 41% dos casos ocorreu reativação da 
doença de Chagas. A forma mais grave é a meningoencefalite, com 100% de letalidade nos casos 
sem tratamento específico e precoce do T. cruzi. O medicamento indicado foi benznidazole, nas 
doses e duração utilizadas na fase aguda em imunocompetentes. O diagnóstico da reativação 
foi comprovado por alta parasitemia, detectada por métodos diretos ou indiretos quantitativos, 
sendo a sua elevação considerada fator preditivo para reativação. A menor sobrevida na 
coinfecção esteve relacionada à reativação da doença de Chagas e às complicações naturais de 
ambas as doenças. O papel do tratamento antirretroviral sobre a evolução da coinfecção ainda 
não pode ser definido pelo conhecimento existente. Conclusões: Apesar da relevância deste 
evento clínico, ainda persistem lacunas a serem preenchidas.
Palavras-chaves: Doença de Chagas. Trypanosoma cruzi. HIV. AIDS. Reativação. 
Imunodeficiência.
The Chagas disease stands as a relevant chronic 
infectious process from the public health1 point 
of view. It is estimated that 14 million people are 
infected and that 60 million are at risk of infection 
whereby in Brazil 1.8 to 2.4 million individuals are 
in the chronic stage of the disease, 1/3 of them 
are in the cardiac and digestive form, generating a 
high morbimortality2. Despite its relevance there 
are still major challenges in understanding various 
aspects of the disease3,4. Due to the vectorial 
transmission control, especially of the main insect 
Triatoma infestans, combined with the transfusional 
transmission control, the acute phase of the disease 
is becoming increasingly rare5, determining that 
the attention is focused on the population with 
chronic infection, as well as other changes occurring 
in the epidemiology of the Chagas disease. This 
fact is based on increased survival of Chagas 
disease patients, urbanization of the population 
amongst other situations and consequently a higher 
probability of comorbidities, infectious or not6. 
Therefore, with the emergence of the human 
immunodeficiency virus (HIV) and the development 
of acquired immunodeficiency syndrome (AIDS), the 
co-infection with the Trypanosoma cruzi (T. cruzi) 
began to be described7. As in other infectious diseases, 
the T. cruzi behaves, potentially, as an opportunist 
microorganism in subjects with immunosuppression 
of any nature, among them, any generated by HIV, 
which is predominant in urban areas8. In Brazil, the 
reactivation of the Chagas disease in people with the 
co-infection was considered as an AIDS defining 
condition in 2003; therefore,  in 2006, the Brazilian 
Network of Attention and Studies on Trypanosoma 
cruzi/HIV Co-infection9,10 was established. Although 
the first case of this association of diseases was 
reported in the 1980s11,12, the frequency that it 
occurs, as well as the reactivation which is clinical 
and laboratorial profile of the subject with a co-
infection, the specific treatment for the T. cruzi and 
antiretroviral and its efficiency, the quantification 
of survival rates and mortality of this individuals 
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TABLE 1 - Number of cases, age and gender of individuals with the co-infection 
T. cruzi/HIV and distribution by country in the period from 1980 to 2010.
            Cases                                                     Cases
Country n % Age (years)  Gender n %
Brazil 222 76.2 minimum 19 male 126 66.3
Argentina 56 19.2  female 64 33.7 
USA 5 1.7 maximum 66 not informed 101 34.7
Chile 5 1.7    
Spain 3 1.0 average 37.3  
Total 291                                  115 (39.5%)  190 65.3
HIV: human immunodeficiency virus; USA: United States of America. 
TABLE 2 - Phase and clinical forms of the Chagas disease in individuals with 
the co-infection T. cruzi/HIV and published in the period from 1980 to 2010.








Not informed 173 59.5
Total 291
HIV: human immunodeficiency virus.
specific research in order to be clarified. This revision aims to verify 
the frequency of the records of the co-infection T. cruzi/HIV and 
describe systematically the main clinical and epidemiological 
aspects found in the literature on the period from 1980 to 2010.
The following databases were used for the research: MEDLINE, 
through PubMed (U.S. National Library of Medicine), Latin 
American and Caribbean Center on Health Sciences Information 
(BIREME), Literature in the Health Sciences in Latin America and 
the Caribbean (LILACS), Scientific Electronic Library (SciELO), 
SciVerse Scopus and The Library Cochrane, in the period between 
1980 and 2010. The terms used as keywords were: ‘Chagas disease 
and HIV and AIDS/doença de Chagas e HIV e AIDS/Tripanosomiasis 
and HIV and AIDS/Tripanosomiase e HIV e AIDS’, in order to no 
lose the articles written in English, Portuguese and Spanish. The 
studies were recovered in full with no previous selection in terms 
of the type of the study. Additionally, in order to exclude repeated 
reports of casuistic or cases based on authors, information about 
cases previously published and institutions responsible for them, it 
was decided to consider the more complete article. Only research 
published in scientific journals were analyzed and abstracts of annals 
of scientific events or personal information were not considered. 
The following data were collected in the research sources: 
intersection among the used sources, number of published articles 
during the period, distribution of articles by decade and years in a 
period, complete citation, country where the research was conducted 
and type of article. From the article retrieved, the following data were 
obtained: number of cases, age, gender, stages and clinical forms 
of the Chagas disease, performance and type of serology for the 
diagnosis of Chagas disease, T. cruzi research realized and method 
used (xenodiagnosis, blood culture, peripheral blood, liquor and 
other fluids, histopathology and molecular biology), presence of 
reactivation of Chagas disease and its location (central nervous 
system, heart, other organs), if there was specific treatment for 
T. cruzi, medication used, dosage and period of use, survival rate 
of the patients, imaging exams to diagnose lesions (tomography or 
MRI), performance and type of antiretroviral treatment, occurrence 
of death and the necropsy. The analyzed data were presented on a 
descriptive way.
There were found and recovered 83 articles in the 30 year 
period researched, corresponding to 2.7 articles per year. Thirty-six 
(50.7%) articles were found in just one of the databases researched, 
being PubMed the one with highest number of articles with a single 
citation (15.5%). Of all the articles, only three were cited in all four 
databases queried.
Since the first citation took place in 198811, there was a 22 
year period in which there were publications about the topic; 
therefore, corresponding to an average of 3.8 articles/year. During 
the 1980s only two (2.4%) articles were published11,12. During the 
1990s, there were 37 (44.6%)13-49 published and during the 2000s, 
44 (53%)53-93, with 1998 having the highest number at 10 (14.1%) 
articles published. Brazil was the country with the highest number 
of publications on the topic, with 43 (51.8%) articles, followed by 
Argentina with 23 (27.7%). This was followed by the United States 
of America with 7 (8.4%), Chile with 4 (4.8%), Spain with 2 (2.4%) 
and Jamaica, Germany, Colombia and Switzerland with one (1.2%) 
citation each. In terms of the types of articles, 63 (75.9%) were 
clinical studies, 1 (1.2%) related to the anatomical pathology and 1 
(1.2%) experimental. In regards to the design of the study, 50 (60.2%) 
were presented as case reports and 14 (16.9%) as a series of cases. In 
13 (15.7%), the form of publication was a topic review, and 3 (3.6%) 
were letters to the editor and 2 (2.4%) editorials.
The number of co-infected cases obtained from the researched 
literature was 291, which corresponds to 9.7 cases/year in average. 
There were 222 (76.2%) cases from Brazil, followed by Argentina 
with 56 (19.2%) cases, United States of America with 5 (1.7%) 
cases, Chile with 5 (1.7%) cases and Spain with 3 (1%) cases. It 
was possible to verify the age in 115 (39.5%) cases ranging between 
19 to 66 years, with an average of 37.3 years. There was, however, one 
record of congenital Chagas disease in a two month old newborn, not 
being considered to calculate the average. The studies reporting only one 
case of the co-infection accounted for 50 articles, and the age average 
of the individuals was of 34.9 years. In regards to the distribution by 
gender, it was possible to obtain this information in 190 (65.3%) cases, 
with 126 (66,3%) male case and 64 (33.6%) female cases (Table 1).
The acute phase of the Chagas disease was reported in only 
six (2%) cases, the remaining (97.9%) were considered to be in 
the chronic phase, distributed in the following clinical forms of 
118 cases: 60 (50.8%) undetermined cases, 44 (37.3%) cardiac 
cases, 6 (5.1%) digestive cases and 8 (6.8%) mixed cases (Table 2).
The serology for the diagnosis of Chagas disease was informed 
in 185 (63.6%) cases, 175 (94.6%) positive. The techniques 
used were enzyme-linked immunoabsorbent assay (ELISA), 
immunofluorescence and indirect hemagglutination and complement 
fixation. Among the methods for identification of the parasite, the 
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DISCUSSION
TABLE 3 - Number of cases and places of reactivation of Chagas disease in 
individuals with the co-infection T. cruzi/HIV and published in the period 
from 1980 to 2010.
Places n %




HIV: human immunodeficiency virus.
TABLE 4 - Number of CD4+ T Cells in individuals with the co-infection T. cruzi/HIV 
and published in the period from 1980 to 2010.
  CD4+ T cells –  CD4+ T cells –
Number CD4+ T cells non reactivation reactivation
Minimum 1 cell/mm3 44 cells/mm3 1 cell/mm3
Maximum 1949 cells/mm3 1949 cells/mm3 551 cells/mm3
Average 339,5 cells/mm3 561,5 cells/mm3 98,4 cells/mm3
HIV: human immunodeficiency virus; CD4: cluster of differentiation 4.
TABLE 5 - Survival in individuals with the co-infection T. cruzi/HIV and 
published in the period from 1980 to 2010.
Survival General Non-reactivation Reactivation
Minimum 1 day 2 months 1 day
Maximum 11 years 11 years 5 years
Média 1,7 years 2,8 years 10,6 months
HIV: human immunodeficiency virus.
direct research was performed in the peripheral blood in 92 (31.6%) 
cases with positivity in 51 (54.4%) and also in the liquor in 64 (22%) 
of the cases, with positivity in 50 (78.1%) cases  and negativity in 14 
(21.9%). On the other hand, in regards to the indirect methods for 
research of the T. cruzi, the xenodiagnosis was used in 104 (35.7%) 
cases with positivity in 97 (93.3%) of them, while the blood culture 
was used in 95 (32.6%) cases with positivity in 75 (78.9%) cases. The 
research by molecular biology utilizing the polymerase chain reaction 
(PCR) was reported in only 7 (2.4%) cases being that in four of them, 
the parasite was recognized from the study of the duodenal biopsy by 
occasion of a high digestive endoscopy. In addition to the duodenum, 
there was identification of the parasite in the skin in three (1%) cases, 
and one (0.3%) case each in the pericardium fluid, ascites, cervix and 
stomach. The histopathological evaluation was reported in 44 (15.1%) 
cases with parasite finding and inflammatory lesion suggesting Chagas 
disease, with 31 (70.4%) in the central nervous system, six (13.6%) in 
the myocardium, four (9%) in the duodenum, three (6.8%) cases in the 
skin and in the cervix and stomach were reported one (2.3%) case each.
There were 120 (41.2%) reported cases of reactivations of 
Chagas disease, 89 (74.2%) cases in the central nervous system, 
and 20 (16.7%) in the myocardium. Other places with reports of 
reactivation included the duodenum with four (3.3%) cases, skin with 
three (2.5%) and one (0.8%) in the cervix, peritoneum, pericardium, 
stomach and eye tissue (Table 3).
The count of CD4 + T cells was reported in 59 (20.3%) cases 
varying from 1 cell/mm3 to 1,949 cells/mm3, with an average of 
340 cell/mm3. In the reactivated cases, the count varied from 1 
cell/mm3 to 551 cells/mm3, with an average of 98 cells/mm3. In the 
cases where there was no reactivation, the count of CD4 + T cells 
varied from 44 cells/mm3 to 1,949 cells/mm3 with an average of 562 
cells/mm3 (Table 4).
The etiologic treatment of the infection by T. cruzi was reported in 
100 (34.4%) cases, having the benznidazole being used in 87 (87%) 
cases, the nifurtimox in 14 (14%) cases, the fluconazole in three (3%), 
the itraconazole in two (2%) and the ketoconazole in two (2%) cases. 
The dosage used was 5mg/kg for the benznidazole and 7mg/kg for the 
nifurtimox, in a time period equal to immunocompetent individuals. 
The minimum survival was one day to a maximum of 11 years, the 
average being 626 days. In the co-infected individuals with reactivation 
of Chagas disease, the survival rate ranged from one day to five years 
and five months, with an average of 10.6 months, and that the highest 
survival rate of reactivation in the central nervous system was five 
years and four months, and in the heart of five years. In the individuals 
where the reactivation did not happen, the survival rate varied from 
two months to 11 years, with an average of 2.8 years (Table 5).
The computerized tomography was registered in 66 (22.7%) 
cases, evidencing pseudotumoral lesions in 59 (89.4%) cases, 
similar lesions to that found in toxoplasmosis in two (3%) cases and 
hydrocephalus, meningoencephalitis and calcifications in one (1.6%) 
case. In two cases, the brain tomography was reported as normal. The 
magnetic resonance was registered in 22 (7.6%) cases, the type of 
lesion being found in the pseudotumoral (100%).
The antiretroviral therapy was reported in 65 (22.3%) cases. 
In five cases, it was reported the use of highly active antiretroviral 
therapy (HAART).
Progression to death was reported in 86 (29.6%) cases, being that 
in 63 (73.3%) of them the reactivation of Chagas disease occurred. 
Amongst this cases, 56 (88.9%) happened in the central nervous 
system and 12 (19%) in the heart. The necropsy was performed in 
25 (29.1%) cases.
This article represents the first systematic evidence of publications 
on the T. cruzi co-infection and HIV. From this analysis is reinforced 
that even though the co-infection Chagas disease/HIV has expanded 
its importance since the advent of AIDS in the 1980s10,11, the subject 
has not been the object of systematic scientific-technical publications 
by what is shown in the number of articles published in the past 30 
years. In this sense, combined with underreporting of this event, 
there are still gaps in terms of clinical and epidemiological aspects, 
comprising prevention, diagnosis, treatment and follow up. This 
observation is not only based on the low amount of articles, but also on 
the type of published studies, mostly case reports, often of single ones.
The other frequent kind or article found is the series of cases 
addressing the reactivation of Chagas disease in the central nervous 
system as a rare and unusual event since the brain is not a usual place 
for lesions in the course of the chronic evolution of this disease. The 
exception to these types of publication was the analysis of a series 
of cases from Brazilian authors81,93 where the topic was discussed in 
a broad way with detailed description of cases of individuals with 
the co-infection, clinical and evolutive profile. Also, the majority of 
articles were published in Latin American countries, led by Brazil, 
reflecting the regional importance of Chagas disease as an endemic 
in this region. The lack of studies with a higher number of follow-
up cases, with cohorts, as those that have been carried addressing 
ischemic cardiomyopathy, high blood pressure, diabetes and other 




In almost all the records, the topic is addressed from the clinical 
description of cases, antomopathological aspects and due to the 
particularities of the HIV infection the non occurrence of studies 
with laboratory animals. As expected, with the publication of the 
first articles about the co-infection, the topic became more explored 
as it occurred with the other diseases, mainly the infectious and 
neoplasic associated with HIV11 infection. Over the last years, 
despite the higher number of publications about the co-infection, 
there were no modifications on the modality of the studies found. 
One of the aspects not yet completely recognized and of extreme 
relevance, refers to the frequency that the co-infection occurs. The 
approach used on this systematic review of the literature may reflect 
an underestimation of this event, since not all the cases can be 
published, or yet, are in different indexing databases of scientific-
technical researches from the ones utilized in this study.
It is likely that other cases were reported in scientific events, 
such as congresses, meetings, dissertations in graduate programs 
or simply were not reported. However, the analysis only of the data 
published in journals, in the way it was done, brings more reliability 
to the interpretations. Therefore, as far as it was possible to revise the 
literature, for the first time the number of cases with the co-infection 
T. cruzi and HIV has been systematized worldwide with 291 subjects.
Brazil has a concentrated AIDS epidemic, considering that the 
prevalence rate of HIV infection is less than 1% in the general population 
and above 5% in population subgroups with higher risk to infection 
including, men who have sex with men, injectable drug users and sex 
workers. In 2004, it was estimated an overall prevalence of 0.6%98. 
Based on this estimate, the country had in 2009 approximately 642,601 
infected people. On the other hand, as from the epidemiological 
surveillance based on the notification of cases of AIDS, from July 
1980 to June 2010, were reported in the country 592,914 cases 
(adults and children). Regarding the Chagas disease, it is estimated 
the existence of approximately 2 million infected individuals10,11. 
In Brazil, in a service of macro-regional scope and reference 
to 50% of the cases of HIV/AIDS patients it was verified that the 
frequency of co-infection was of 1.3%56,93. Based on this study, for the 
total of individuals infected with HIV without AIDS98, it is estimated 
the existence of approximately 8,354 people with the co-infection in 
Brazil. Considering the cases of AIDS, the country should have an 
additional number of 7,708 co-infection cases, totaling 16,062 cases. 
As of the 291 cases described around the world, 222 are in Brazil. 
It is very likely that this number is truly underestimated, with the 
majority of the cases not being reported or in a worst scenario, not 
diagnosed. In the Latin America, only Brazil, Argentina and Chile 
described cases. Following the same reasoning previously used for 
Brazil, there are 1.7 million individuals with HIV/AIDS in the Latin 
America99, the estimate for the frequency of co-infection in this region 
would be of 21,420.
There is controversy regarding the first description of the co-
infection. Argentinean authors7 refer to as the first description of a 
case of Chagas disease in the central nervous system published in 
June 1990, mimicking a tumor in an individual with AIDS. However, 
in 1992, authors in the United States of America18 published a case 
describing the Chagas disease as another cause of brain mass in 
AIDS patient, emphasizing this to be the first of co-infection since 
the Argentinean authors did not confirm the trypanosomiasis 
for not having performed culturing on brain fragments for the 
identification of T. cruzi. The controversy prompted the exchange 
of mail between the authors with justifications and addition of 
information, confirming that this is the first case of a person with 
acquired immunodeficiency and chagasic encephalitis. However, 
published on two occasions by Brazilian authors12,13, prior to the 
controversy already mentioned, proven cases of the presence of 
T. cruzi in the liquor of individuals with HIV infection in which the 
denomination reactivation of Chagas disease had been used before. 
In none of these two studies, the Argentinean or the American6,15, the 
Brazilian studies were cited. The fact that the articles were published 
in Brazilian journals and in Portuguese may justify their non citation. 
For the diagnostic of the co-infection, it is sufficient the concurrence 
of both diseases in the same individual, regardless of place of affection 
by the T. cruzi infection. The different locations of it within the 
organism only reflect the cosmopolitan distribution of the Protozoa. 
Thus the first description of the co-infection is of Brazilian authorship, 
as well as the cerebral damage by T. cruzi in this situation.
The age group in which co-infected individuals are found is 
broad, but the average age found shows that these are young adults 
for the most part. This reflects the variation of the epidemiology of 
the HIV/AIDS epidemic since its description in the 1980s94. The 
epidemiology of the Chagas disease also suffered changes in the 
last decades in view of the control of its main vector, T. infestans, the 
controlling of the transmission through transfusion, generating the 
aging of the infected population1,10,11. This reflected on the profile of 
the co-infected individual, since the description of the co-infection 
on a pediatric population was not registered with the exception of 
the cases of congenital infection in neonates from mother with the 
co-infection29. In this way, so far this population expresses more the 
behavior of the HIV/AIDS infection epidemic in relation to the age 
than that of the Chagasic endemic, and thereafter accompanying 
the aging tendency of the HIV infected individuals in view of the 
epidemiological changes in relation to the transmission mechanisms 
of the virus and in response to the HAART. The higher frequency of 
men amongst the co-infected individuals, as well as the age, reflects 
the epidemiological profile of the infection by HIV94.
The almost total prevalence of co-infected individuals in the 
chronic phase of the Chagas disease (98%) reflects the control of 
the disease in its main means of transmission11. This is particularly 
true in Brazil, where the transmission of T. cruzi by T. infestans was 
considered interrupted since 2006 by the World Health Organization 
(WHO)/Pan American Health Organization (PAHO)5. Although 
the same wasn’t observed in all Latin America, the higher amount of 
cases related by Brazilian studies must be responsible for the result 
found. Operational aspects of national health systems of different 
countries in terms of timely diagnosis of both infections certainly 
fall within this perspective11. The distribution of the cases on the 
different clinical forms of the chronic phase, predominantly of the 
indeterminate form, followed by the cardiopathy, digestive and 
mixed corresponds to the natural history of this phase of the Chagas 
disease95. Therefore, on the series of cases published in Brazil81,93 the 
occurrence of the different clinical forms overlaps that found in this 
revision of all the cases, there being no report of any in the acute phase. 
The diagnostic of the Chagas disease was serologic and followed 
the WHO96 criteria, been used the methods most recently employed, 
such as the ELISA, indirect immunofluorescence and passive 
hemagglutination in the detection of antibodies for T. cruzi. Positivity 
was reported on the majority of the cases. However, the finding of 
5.4% nonreactive serological proof may result in misdiagnosis and 
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should not be undervalued when the Chagas disease diagnostic seems 
likely by other methods. The immunological disorders involving 
the pathogenesis of the HIV infection, especially in the presence of 
AIDS, may be responsible for these non-reactive serological proofs 
in the presence of Chagas disease97. This way the finding of the 
parasite by direct or indirect methods is pointed as the sure diagnosis 
of Chagas disease, while the positive serology configures the safety 
diagnosis12,13. The xenodiagnosis was the most utilized indirect research 
method of T. cruzi, with high (93%) positivity, followed by the blood 
culture which showed lower (79%) positivity although high. It was 
not observed in all the reports uniformity on the indirect methods, 
although for the xenodiagnosis the Schenone98 was the most used 
technique. The results however were positive or negative for most 
of the cases reported, showing that the analyses was conducted in a 
group of nymphs, making the examination of qualitative nature. As 
for the blood culture, although the mean of culture reported has been 
the LIT (liver infusion tryptose), the same kind of interpretation is 
subject to be made, since usually the amount of blood used for this 
purpose is one milliliter. Although both exams reflect an increased 
parasitemia when positive, along the qualitative lines it can be found in 
immunocompetent hosts on the natural course of the Chagas disease. 
More recently both exams have been receiving special care in order to 
make them quantitative. Therefore, 30ml of blood distributed in vials 
with five milliliters have been used for the T. cruzi culture, as well as 
the xenodiagnosis started to be analyzed quantitatively through the 
individual examination of the nymphs, obtaining the proportion of 
parasitized nymphs, as reported by Brazilian authors in a series of 
cases81. This way was possible to quantify the parasitemia and suggest 
a classification of very high when the parasites could be identified by 
microscopic examination of the peripheral blood, high when more than 
20% of the utilized nymphs on the xenodiagnosis were infected and, 
low, when less than 20% of those were found parasitized by T. cruzi.
The molecular biology by means of the polymerase chain reaction 
technique, is already well studied in Chagas disese101, but has not 
been a frequently utilized method for indirect research of T. cruzi 
in the presence of the co-infection with HIV/AIDS. However, it 
was described in two (0.7%) cases used for diagnostic confirmation 
in peripheral blood92, and on the study of the parasite in duodenal 
biopsies in four co-infected individuals51. The samples were positive 
and in all of them were found nests of amastigote forms of T. cruzi on 
histological examination. This values the PCR method of the indirect 
study of the parasite in individuals with the co-infection. In only 
one case, the real time PCR technique was utilized as cure criteria 
in a case of reactivation of Chagas disease of long survival, serving 
as criteria to interrupt the etiologic treatment, once the result was 
negative90. Other authors utilized the PCR for lineage specifications 
of the parasite isolated by other methods62,64,73.
The study of the parasite on a direct way took as reference, mainly, 
the peripheral blood and liquor.  However, the utilized method was 
not specified in some articles29,30,32,70. Yet, the research between slide 
and cover slip of fresh material, thick smear with May-Grunwald-
Giemsa coloration, Strout, microhematocrit and buffy-coat was 
reported in several studies in order to increase the sensitivity 
when verifying the presence of the protozoa23,33,39,42,45,46,63,68,81, not 
having, however, in any of those reference to the superiority of this 
methods compared to the study of the parasite directly on fresh 
material. The peripheral blood was the site where the parasite was 
most searched, but the liquor was where the largest proportion of 
positivity on the T. cruzi research (78%) occurred, which shows that 
it is indispensable the use of this evaluation during the investigation 
of cerebral impairment in patients with the co-infection, considering 
the feasibility of the exam. The study on the liquor of co-infected 
individuals, but without evidence of alterations in the nervous 
system, was not related in the researched literature. The finding of 
the parasite in other organic fluids was related in the pericardial32 and 
ascetic40 fluid which shows that in situations of high parasitemia, the 
T. cruzi can spread, and during the co-infection it must be searched 
systematically in all organic fluids. The histopathological evaluation 
was reported in only 15% of the cases, with the places most studied 
the central nervous system (70%) and the myocardium (14%), places 
where the Chagas disease usually has its most severe forms during the 
acute phase96. Also, were described histopathological evaluations in 
the stomach32, duodenum51, skin48,61,81 and uterine cervix55. In all this 
locations were found parasites and inflammatory reaction suggestive 
of the Chagas disease. Apart of the myocardium, the other locations 
are not those where these anatomopathological findings are often 
described on Chagas disease. Therefore, they must be considered as 
enhanced parasitemia dependents in immunosuppressed individuals 
and are data considered by the authors as indications of reactivations 
of Chagas disease, understanding that reactivation comprises the 
presence of the acute disease and high parasitemia in the course of 
the chronic phase, and may be more or less severe, depending on the 
stricken place in the organism. It is emphasized that in Brazil, this 
reactivation condition is considered for the definition of an AIDS9 case.
The majority of the articles report the reactivation in the 
central nervous system and in the myocardium, usually severe 
cases, with fatal outcome38. However, just as there are difficulties to 
know the exact number of individuals co-infected, this also occurs 
regarding the frequency that these reactivate the Chagas disease, 
a pathognomonic clinical event. However, when the parasitemia 
is analyzed by xenodiagnosis or blood culture, the co-infected 
individuals have a higher chagasic parasitemia than patients without 
the co-infection with the HIV, suggesting that this reactivation may 
occur asymptomatic, with a higher frequency44,60,61. In this revision, it 
was reported the occurrence of 41,2% of reactivations, this percentage 
higher than the ones related in series of cases, which varies between 
10 and 15%81,93,97, reflecting that, probably, the more severe cases 
must have been diagnosed and related. Considering the estimates 
presented in this review, the occurrence of reactivations of Chagas 
disease in the co-infection with HIV is underestimated99,100.
The reactivation was described in the majority of the articles as 
occurring in the central nervous system, responsible by 74% of the 
events, followed by heart, 17%, clinically characterized by signs of 
acute disease being fever the main manifestation. In relation to the 
clinical focus of each organ affected, this was nonspecific, ranging 
to the central nervous system from headache, signs of intracranial 
hypertension, seizures, motor location and coma, generating 
diagnostic confusion, mainly with toxoplasmosis and tumors of the 
central nervous system37,65,66,75,84. For the heart, it consists of triggering 
or exacerbating congestive heart failure, arrhythmias, atrioventricular, 
heart and fascicular blocks22,27,34,42. The fact that the clinical picture 
presented in the reactivation in the heart, usually occurred in the 
natural evolution of the chronic chagasic cardiopathy88,102 making 
the diagnosis difficult, unlike the central nervous system which does 
not present exuberant symptomatology in the chronic phase of the 
disease. Other less common locations of reactivations cited were 
the pericardium32, peritoneum40, skin48, intestine32,51 and cervix55. 
Although the reactivation has been described in the extrinsic eye 
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muscles in a case of co-infection with reactivation of the Chagas disease 
in the brain47, parasites were not found at the lesion site, only myositis. 
It is a constant in all articles published, that the identification of T. cruzi 
at the place where the reactivation occurred has been essential for this 
diagnosis. Thus, although likely in the described case, this possibility 
should not be considered as ocular reactivation of Chagas disease. 
A concern expressed by various authors regards the predictive 
factors that may occur before the reactivation, allowing a preventive 
action strategy or mainly the specific treatment. Such factors have 
had the parasitemia as its main predictor7,81. The parasitemia must be 
identified by direct methods in blood or other organic fluids, always 
reflecting high intensity. For the indirect methods, xenodiagnosis and 
blood culture, there is a need that they are quantitative for the same 
purpose. However, in some cases the high parasitemia occurs for a 
long time without a reactivation happening, demonstrating that other 
deterrent factors of reactivation might exist81. The immunosuppression 
expressed by the levels of CD4 T cell bellow 200 cells/mm3 would be 
another predictive factor, since the reactivation is described most of the 
times in individuals with AIDS. However, in the researched literature 
the Chagas disease reactivation occurred in individuals with the CD4 T 
cells of up to 382 cells/mm3,23. Other similar reports with CD4 T cells 
above 200 cells/mm3 and confirmed reactivation by high parasitemia 
with T. cruzi detected on peripheral blood, pericardial fluid, myocardial 
and quantitative xenodiagnosis have been described34,42. The opposite 
is also found, that is, CD4 T cells count bellow 200 cells/mm3 without 
reactivation35. However in this cases the average count of CD4 T 
cells was much higher, 562 cells/mm3, than on those reactivated, 98 
cells/mm3. But some few non reactivated cases present a very low 
CD4 T cells count42. Although there are discrepancies amongst the 
published studies, the majority of the reactivated cases, occurred in 
individuals with the CD4 T cells count inferior to 200 cells/mm3 and 
the average value of these cells are well below this parameter, so, it is 
acceptable to consider this data as predictive to reactivation. The same 
has been observed in relation to the viral load that as the lymphocyte 
count reflects the degree of immunosuppression of the HIV infected 
patient. The data revised of the researched literature head to the fact 
that, in the infected individual, the monitoring of the reactivation 
must be based on the evaluation of the parasitemia by T. cruzi, taking 
into account the degree of immunity: the more immunosuppressed, 
the greater should be the monitoring of the parasitemia. The 
degree of immunity in the co-infected individual would be given 
mainly by the CD4 T cells count, but also by the viral load.
As to the diagnosis of Chagas disease reactivation, it involves 
the clinical approach, the imaging exams and the observation of the 
parasite in the reactivated place, for most of the times. The clinical 
condition is nonspecific for including reactions from the acute phase: 
fever, poor general condition, disorientation, hepatosplenomegaly, 
lymphadenopathy, among others22,23,32,42,81,93. Specifically, the 
clinical condition refers to the place of the reactivation. Therefore, 
the neurological condition draws more the attention25,52,65,66,87 that 
in most of the times has toxoplasmosis as the main diagnosis in 
view to the frequency that this condition happens in HIV infected 
individuals33,37,68. In the heart, the symptomatology and the physical 
aspects overlap those seen on the natural evolution of the chronic 
chagasic cardiopathy, hindering the diagnosis22,27,34,42,88.
This way, the imaging exams have great importance in the 
identification of lesions, mainly in the central nervous system. There 
is no substantial difference between the findings on the computed 
tomography (CT) of the head and those observed on magnetic 
resonance imaging (MRI), whereas the lesion most often found is 
the pseudotumoral. These lesions, usually, are hypodense, single or 
multiple, with or without ring reinforcement when using contrast. 
White matter of the brain hemispheres happened more frequently. 
Some authors have searched for aspects in the tomographic images 
and on the MRI of the brain capable of defining the chagasic etiology, 
as the prevalence of these in the subcortical areas33,37,68. The purpose 
would be to make a differential diagnosis with the toxoplasmosis, 
whose involvement of the thalamus and the basal ganglia happen more 
frequently. However, the chagasic lesions are widely distributed in the 
central nervous system and this should not be generalized, and the 
Chagas disease diagnosis should be among those differentials, especially 
in the cases where the epidemiological history is predictive. In two 
cases, there was description that the CT of the brain was normal32. In 
one of them, the reactivation happened in the heart and on the other, 
although there was a detection of parasites in the peripheral blood and 
hemiparesis, it was not possible to define the etiology of the involvement 
of the brain. The patient died and the brain could not be examined.
The survival of the patients was highly variable and was 
related to some factors, the main one being the reactivation of the 
Chagas disease in the central nervous system, where the mortality 
reaches 100% in the cases without specific treatment81,93. When 
the reactivation does not occur or is controlled, the survival is 
directly related to the complications found in the natural evolution 
of the Chagas disease and, mainly, of the infection by HIV/AIDS. 
In the cases with reactivation the studies, in general, consider the 
survival severely reduced in the following conditions: when there is 
compromising of the central nervous system, the late diagnosis of 
chagasic etiology of the neurological lesion and the late introduction 
of the specific therapy for the T. cruzi81,93. The last two situations are 
those that can modify and influence the prognosis of the patients. 
When such interventions don’t occur, there is no description of 
spontaneous resolution of the chagasic meningoencephalitis. Thus, 
by separating the reactivated cases from the non reactivated, the 
average survival rate of the first group was 11 months. As for the non 
reactivated cases, the survival rate was of 34 months, in other words, 
three times longer. The longest survival amongst the reactivated cases 
was of approximately six years and it happened in the heart27,35. When 
the reactivation was in the central nervous system, the longest survival 
was three years14,81 happening in two cases. In both, there was specific 
treatment of the infection by T. cruzi with benznidazole, itraconazole 
and fluconazole in one and only with benznidazole in another, and 
that on this last one it was utilized secondary prophylaxis. In the 
cases with higher survival where there was reactivation in the heart, 
the patients were treated with benznidazole35.
The influence that the immunological reconstitution reached 
by the antiretroviral treatment determines the natural evolution of 
the co-infection Chagas/HIV/AIDS is not yet found defined in the 
researched literature77,81. In theory, once this is established, mainly by 
the medications of the HAART in the control of the viral replication 
and recovering the immunological system, the Chagas disease should 
follow its natural course as in the immunocompetent individual. For 
the other infectious diseases associated to the HIV infection this 
seems to occur8,50. However, the few cases already reported about 
the co-infection Chagas/HIV/AIDS and the incomplete information 
about the antiretroviral treatment, as drug specifications, length of 
use, compliance with treatment, intolerance, side effects, response 
of the patient to the immunological recovery, makes it difficult to 
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establish in this revision the real impact of this treatment on the 
reactivation of Chagas disease in co-infected patients. In the largest 
series of cases with the co-infection published by Brazilian authors81, 
is where the best reports about the antiretroviral treatment were, 
being used in the period of monitoring of the patients receiving single, 
double and triple therapy, with 28 cases using HAART. Although the 
authors have not discussed in detail the subject, the antiretroviral 
therapy did not change significantly the T. cruzi parasitemia in the 
cases where it was classified as high, even when an increase of the 
CD4 T cells takes place. In the cases where the parasitemia was low, 
the evolution was the usual of immunocompetent chagasic patients. 
Therefore, efforts should continue to be made to establish the role 
that the medicinal immunological reconstitution would have in the 
control of the Chagas disease reactivation in individuals co-infected 
with HIV/AIDS.
Although the overall mortality verified was 30%, it occurred in 
73% of the cases in which there was reactivation of Chagas disease. 
Of these deaths, 89% had reactivation in the central nervous system, 
reinforcing what was previously discussed and the necessity of 
monitoring this reactivation.
The co-infection T. cruzi/HIV has not been systematically 
evaluated in the majority of the endemic countries for Chagas disease.
The topic has been published, mainly as case reports or small 
series of it, with incomplete information and diverse codes of 
conduct.
Probably, the number of subjects co-infected and published on 
the literature until now is underestimated.
The epidemiological profile of the co-infected subjects is: adult 
male, native or from endemic regions, with serological diagnosis in 
the indeterminate form of the chronic phase and reactivation of the 
Chagas disease.
The reactivation diagnosis its suspected when the subject with 
the co-infection presents a clinical profile of acute disease or clinical 
decompensation of the natural evolution of the chronic phase, clinical 
profile of organic impairment uncommon in Chagas disease or 
presence of pseudotumoral brain lesions on imaging exams.
The high parasitemia is recognized as the main predictive factor 
of the Chagas disease reactivation.
In the presence of co-infection, the count of T lymphocytes 
CD4+ bellow 200 cells/mm3 or the high HIV viral load are indicating 
factors for the monitoring of the parasitemia.
The reactivation diagnosis is verified when there is a high 
parasitemia detected by direct or indirect quantitative methods.
The specific treatment for the T. cruzi is a formal recommendation 
on reactivation, starting as early as possible with benznidazole on 
the doses and length of use as indicate on the acute phase of natural 
evolution of the Chagas disease. Other medications, as nifurtimox, 
azole derivatives and allopurinol should be considered on the 
treatment of the reactivation when there is impediment for the use 
of the benznidazole.
The lower survival rate of subjects with the co-infection is related 
to the presence of the reactivation of Chagas disease and the natural 
complications of both diseases.
The role of the antiretroviral treatment on the evolution of 
the patient with the co-infection cannot yet be determined by the 
knowledge currently existing.
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